PIONEERING STUDY ON NASAL SPRAY PROBIOTICS (LIVESPO® NAVAX): A BREAKTHROUGH IN PREVENTING RESPIRATORY INFECTIONS IN CHILDREN

Recently, the Spobiotic Research Center collaborated with Hanoi Medical University to conduct the study titled “Efficacy of Saline Solution and Probiotic Products in Preventing Upper Respiratory Infections in Children Aged 2 to 6 in Son Tay Town, Hanoi, 2024.” This study, led by Assoc. Prof. Dr. Nguyen Thi Hoai Thu, was reviewed and accepted by the Institute for Preventive Medicine and Public Health, Hanoi Medical University. This collaboration marks a significant advancement in probiotic research, aiming to support respiratory disease prevention in young children and reduce antibiotic dependency, especially in the field of preventive healthcare

Associate Professor, Dr. Nguyen Thi Hoai Thu and the thesis acceptance council at Hanoi Medical University

This is the first study in the world to demonstrate the safety and superior effectiveness of nasal spray probiotics containing Bacillus spores (LiveSpo® NAVAX and LiveSpo® NAVAX KIDS) in preventing and reducing the recurrence of upper respiratory tract infections in children. Clinical trial results revealed that after 14 and 28 days of use, LiveSpo® NAVAX and LiveSpo® NAVAX KIDS effectively reduced typical respiratory symptoms-such as runny nose, sinusitis, hoarseness, pharyngitis, and tonsillitis compared to baseline and in comparison, with saline solution.

A key highlight of this research is the outstanding ability of LiveSpo® NAVAX and LiveSpo® NAVAX KIDS to prevent pathogenic viruses and bacteria, significantly reducing infection rates and the risk of viral infections such as including RSV, influenza, and rhinovirus, compared to physiological saline. Additionally, probiotics have shown the ability to regulate immunity, strengthening respiratory defenses and significantly reduce the rate of children needing to miss school or take antibiotics, anti-inflammatory drugs, etc.

The study received an “Excellent”  by the evaluation committee due to its high applicability and safety for children. LiveSpo® NAVAX promises to become a potential solution in preventing respiratory tract infections, especially during the changing seasons, helping to minimize dependence on antibiotics in the treatment of respiratory infections in children.

LIVESPO® NAVAX: A BREAKTHROUGH PRODUCT IN PREVENTING RESPIRATORY DISEASES IN CHILDREN, REPORTED AT THE 27TH NATIONAL SCIENTIFIC CONFERENCE ON OTOLARYNGOLOGY & HEAD AND NECK SURGERY

Four staff members from the Spobio Research Center, ANABIO R&D Ltd, represented the company at the 27th National Scientific Conference on Otolaryngology & Head and Neck Surgery, held from November 1st to 3rd, 2024, in Ninh Binh City, Ninh Binh Province. This prestigious event attracted numerous leading experts, doctors, and pharmacists from both domestic and international communities to discuss, share, and update each other on prominent advancements in the field of Otolaryngology.

Assoc. Prof. Dr. MD. Pham Tran Anh (center), along with representatives staff members from ANABIO R&D Ltd, attended the conference

At the conference, Assoc. Prof. Dr. MD. Pham Tran Anh, who works at the Central Otolaryngology Hospital and is also a lecturer at the Department of Otolaryngology, Hanoi Medical University, presented a report titled “Effectiveness of Nasal-spraying Bacillus Spores in Preventing Respiratory Tract Infections in Children: Results from the Community Intervention Study 2023-2024.” This report is part of a scientific project in collaboration with the Institute of Preventive Medicine and Public Health, Hanoi Medical University, and the Spobio Research Center, ANABIO R&D Ltd. The report highlighted the safety and superior efficacy of the LiveSpo® NAVAX and LiveSpo® NAVAX KIDS products in protecting children’s respiratory health. Specifically, LiveSpo® NAVAX significantly reduced the incidence of typical respiratory infection symptoms such as runny nose, sinusitis, hoarseness, sore throat, and tonsillitis by up to 60% after 14 and 28 days of use. Furthermore, the rate of children missing school due to illness and the use of antibiotics and anti-inflammatory medications also showed a significant decrease. Notably, LiveSpo® NAVAX and LiveSpo® NAVAX KIDS helped reduce the rate of bacterial infections by up to 70% and decreased the risk of viral infections such as RSV and influenza by more than 11 folds, showing superior results compared to the use of saline solution.

The study results present new opportunities for using Bacillus spores to prevent respiratory diseases in children, especially during seasonal changes. The report by Assoc. Prof. Dr. MD. Pham Tran Anh received considerable attention and high praise from leading experts and doctors in the field of Otolaryngology.

Assoc. Prof. Dr. MD. Pham Tran Anh presenting at Scientific Session 4: Pediatric Otorhinolaryngology

Outside of the report sessions, the booth showcasing LiveSpo® NAVAX and LiveSpo® NAVAX KIDS also drew considerable attention from experts and doctors. Delegates expressed special interest in the effectiveness of these products in preventing respiratory diseases in children.

Photo of the booth showcasing LiveSpo® NAVAX products

Welcome Mr. Lukasz from the investor Mekong Capital to visit the Spobiotic Research Center.

On September 21, 2024, the ANABIO Spobiotic Research Center (ANABIO R&D) had the honor of welcoming Mr. Lukasz – an investor from Mekong Capital – to visit its Center.

During the visit, Mr. Lukasz was briefed by the R&D specialists at the Center on the research and development processes, as well as the outstanding efficacy of the probiotic products currently in development. These results, validated through clinical trials, not only confirm the quality of the products but also stand as evidence of the company’s commitment to delivering breakthrough, reliable health solutions.

Mr. Lukasz highly appreciated the efforts and achievements of the Center’s staff, and expressed strong confidence in the company’s potential to shape the probiotic market in Vietnam. He also offered strategic recommendations for upgrading infrastructure and expanding the research center to position the company as an internationally recognized biotech enterprise. According to Mr. Lukasz, with its bold direction and long-term vision, the company has the potential to become a “tech unicorn” – directly competing with the world’s leading bioproduct corporations. Mr. Lukasz’s visit underscores the company’s growing appeal on the international stage and provides strong motivation for continued investment in research and development. This support reinforces the company’s mission to elevate the LiveSpo brand of probiotics globally, accompanying consumers worldwide on their journey toward comprehensive health protection

Here are a few images from the visit:

Dr. Nguyen Hoa Anh, Director of ANABIO R&D Co., Ltd., welcomes Mr. Lukasz.
Mr. Lukasz visits the Central Laboratory.

The latest discovery in research on the effects of Bacillus clausii probiotic spores (LiveSpo CLAUSY) has just been published in the prestigious international journal Scientific Reports-Nature.

The research team at the National Children’s Hospital and the Spobiotic Research Center of ANABIO R&D has published impressive results on the effectiveness of liquid Bacillus clausii spores (LiveSpo CLAUSY, Bacillus clausii concentration ≥ 2 billion/5 mL vial) in supporting the treatment of prolonged diarrhea in children.

This clinical trial marks a significant advancement in understanding and treating pediatric diarrhea. The probiotic product LiveSpo CLAUSY is not only safe for children but also shortens the treatment duration by 2-3 days and enhances effectiveness by up to 50-60%, depending on specific symptoms. Notably, the product can reduce the excessive secretion of pro-inflammatory cytokines by up to 29%, a key factor in reducing inflammation and restoring the intestinal mucosa.

This breakthrough brings new hope for children suffering from prolonged diarrhea and opens up promising prospects for research and treatment of other gastrointestinal diseases.

International Conference on Microbiology and One Health

On August 11, 2024, the 2nd International Conference on Microbiology and One Health (MOH-VN 2024) took place at the International Centre for Interdisciplinary Science and Education (ICISE) in Quy Nhon, Binh Dinh. The conference attracted nearly 140 speakers, scientists, and doctors from 25 countries and territories.

The Spobio Research Center – ANABIO R&D Co., Ltd. sent two representatives to attend the conference and present a report on “Bacillus Spore Probiotics: Enhancing Diarrhea Treatment in Children while Reducing Antibiotic ependence by Regulating Immune Responses and Restoring Gut Microbiota.” The report received significant attention and appreciation from many of the attendees.

At the conference, scientists and researchers engaged in in-depth discussions about the “One Health” model, a holistic approach that links human health closely with overall environmental health. They aimed to develop new research directions and seek comprehensive solutions to protect public health. The conference also served as a platform for networking, knowledge exchange, and generating new ideas for “a future without antibiotics.”

Below are some images from the conference:

A representative from the Spobio Center presented the report at the Conference.
Staff from the Spobio Center attended the Conference.
Hosted By Wordpress Clusters